Hidradenitis Suppurativa Market is Predicted to Cross USD 7 Billion by 2036 Owing to the Robust Pipeline Development | DelveInsight

The growth of the hidradenitis suppurativa market is expected to be mainly driven by rising awareness and access to treatment, as well as robust pipeline activity comprising promising therapies such as Eltrekibart (Eli Lilly), Lutikizumab (AbbVie), Sonelokimab (MoonLake Immunotherapeutics), Brepocitinib (Priovant Therapeutics), Spesolimab (Boehringer Ingelheim), Orismilast (UNION Therapeutics), Povorcitinib (Incyte Corporation), and others in the 7MM, reports DelveInsight

Recently published Hidradenitis Suppurativa Market Insights report includes a comprehensive understanding of current treatment practices, hidradenitis suppurativa emerging drugs, market share of hidradenitis suppurativaindividual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Hidradenitis Suppurativa Market Summary

* In 2025, the total market size for hidradenitis suppurativa in the 7MM was approximately USD 1.7 billion, and adalimumab (HUMIRA) and its biosimilars accounted for a major share.

* The US accounted for the highest market size of hidradenitis suppurativa in 2025, i.e. approximately 80% in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan.

* The total diagnosed prevalent cases of hidradenitis suppurativa in the 7MM were approximately 1.8 million cases in 2025.
* Leading hidradenitis suppurativa companies, such as Eli Lilly, AbbVie, MoonLake Immunotherapeutics, Priovant Therapeutics, Boehringer Ingelheim, UNION Therapeutics, Incyte Corporation, and others, are developing new hidradenitis suppurativa treatment drugs that can be available in the hidradenitis suppurativa market in the coming years.
* The promising hidradenitis suppurativa therapies in clinical trials include Eltrekibart, Lutikizumab, Sonelokimab, Brepocitinib, Spesolimab, Orismilast, Povorcitinib, and others.

Download report on global HS market valuation and projection to 2036 @ [https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=scpr]

Key Factors Driving the Growth of the Hidradenitis Suppurativa Market

* Increasing Hidradenitis Suppurativa Prevalence and Diagnosis Rates: The global prevalence of HS is rising, with estimates suggesting 1-4% of the population may be affected. Growing disease awareness among patients and healthcare providers has led to higher diagnosis rates and increased demand for treatment.
* Emerging Therapeutic Options for ADA-Refractory Hidradenitis Suppurativa: Anti-IL-17 and anti-IL-1 inhibition are promising therapeutic options for ADA-refractory moderate-to-severe hidradenitis suppurativa.
* Emergence of Novel Drug Classes: The hidradenitis suppurativa market has a diverse pipeline targeting Interleukins (i.e., IL-17, IL-36), anti-TNF, JAKi, and anti-complement factors, which are contributing to the progression of the market
* Emergence of Oral Therapies Enhancing Patient Convenience: Emerging therapies are coming with patient-convenient RoA, such as RINVOQ, povorcitinib, and orismilast, which are given by oral route.
* Next-Generation Hidradenitis Suppurativa Therapies Shaping the Future: Some of the drugs in the pipeline include Eltrekibart (Eli Lilly), Sonelokimab (MoonLake Immunotherapeutics), Brepocitinib (Priovant Therapeutics), Spesolimab (Boehringer Ingelheim), Orismilast (UNION Therapeutics), Povorcitinib (Incyte Corporation), and others.

Hidradenitis Suppurativa Market Analysis

* Systemic therapies, primarily antibiotics in combination with retinoids, remain the mainstay of treatment for hidradenitis suppurativa.
* Topical therapies are mainly utilized in patients with mild to moderate disease severity.
* Adalimumab (HUMIRA), secukinumab (COSENTYX), and bimekizumab (BIMZELX) are approved for the treatment of moderate-to-severe hidradenitis suppurativa.
* Adalimumab, AbbVie's flagship biologic, dominated the hidradenitis suppurativa market for years due to robust patent protection, but loss of exclusivity in Europe (2016) and the US (2018) enabled rapid biosimilar entry and market erosion.
* Despite its widespread use, HUMIRA often demonstrates suboptimal efficacy as monotherapy in hidradenitis suppurativa, frequently necessitating adjunctive antibiotics or surgical intervention.
* Secukinumab leveraged first-mover advantage and strong launch momentum in hidradenitis suppurativa; however, bimekizumab represents a growing competitive threat due to superior efficacy versus both secukinumab and adalimumab.
* While Novartis benefited from early regulatory approval of secukinumab, bimekizumab's differentiated clinical profile may increasingly influence prescriber preference and gradually erode secukinumab's market share.
* Emerging therapeutic options such as Eltrekibart (Eli Lilly), Lutikizumab (AbbVie), Sonelokimab (MoonLake Immunotherapeutics), Brepocitinib (Priovant Therapeutics), Spesolimab (Boehringer Ingelheim), Orismilast (UNION Therapeutics), Povorcitinib (Incyte Corporation), and others have the potential to address unmet needs in patients who are refractory to currently available treatments.
* The hidradenitis suppurativa market is entering an unprecedented phase of rapid growth, supported by a diverse and expanding pipeline.
* The evolving pipeline targets multiple mechanisms of action, including interleukins (IL-17, IL-36), anti-TNF agents, JAK inhibitors, and anti-complement therapies.

Hidradenitis Suppurativa Competitive Landscape

Some of the hidradenitis suppurativa drugs in clinical trials include Eltrekibart (Eli Lilly), Lutikizumab (AbbVie), Sonelokimab (MoonLake Immunotherapeutics), Brepocitinib (Priovant Therapeutics), Spesolimab (Boehringer Ingelheim), Orismilast (UNION Therapeutics), Povorcitinib (Incyte Corporation), and others.

Sadaf Javed, Manager of Forecasting and Analytics at DelveInsight, commented that dual- and trispecific agents are present in the emerging pipeline, such as BIMZELX, Sonelokimab, and Lutikizumab, which could improve patient outcomes.

MoonLake Immunotherapeutics' Sonelokimab is an experimental humanized nanobody of approximately 40 kDa, composed of three heavy-chain variable (VHH) domains connected by flexible glycine-serine linkers. Two of these domains enable sonelokimab to selectively bind IL-17A and IL-17F with high affinity, thereby inhibiting the natural IL-17 dimers IL-17A/A, IL-17A/F, and IL-17F/F. The drug is being investigated in the Phase III VELA-TEEN trial for adolescents with moderate-to-severe hidradenitis suppurativa, as well as in the Phase III VELA-1 (NCT06411899) and VELA-2 (NCT06411379) trials in adult patients.

Incyte's Povorcitinib is an oral, selective JAK1 inhibitor under development that reduces abscesses and inflammatory nodules in patients with moderate-to-severe hidradenitis suppurativa. It is currently in Phase III clinical testing, with recent clinical data expected to support regulatory submissions in the United States in early 2026.

Eli Lilly's Eltrekibart is an investigational monoclonal antibody targeting CXCR1/2 ligands. It blocks ELR+ CXC chemokine-induced calcium mobilization, CXCR2 internalization, and chemotaxis in vitro, as well as neutrophil mobilization in vivo, without affecting other neutrophil functions. Eltrekibart is presently being evaluated in a Phase II trial for efficacy and safety in adults with moderate-to-severe hidradenitis suppurativa.

The anticipated launch of these emerging therapies are poised to transform the hidradenitis suppurativa market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the hidradenitis suppurativa market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about HS pipeline drugs and clinical stages @ [https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=scpr]

Recent Developments in the Hidradenitis Suppurativa Market

* In January 2026, MoonLake Immunotherapeutics provided an update following positive feedback from the US Food and Drug Administration (FDA) on the clinical evidence strategy for sonelokimab in hidradenitis suppurativa, following a Type B meeting requested by the company.
* In November 2025, MoonLake Immunotherapeutics announced key upcoming clinical milestones for sonelokimab in hidradenitis suppurativa. The company expects to report 52-week data from the Phase III VELA-1 and VELA-2 trials in adult hidradenitis suppurativa in Q2 2026. In addition, the primary endpoint readout from the Phase III VELA-TEEN trial, evaluating sonelokimab in adolescent patients with hidradenitis suppurativa, is anticipated in Q2 2026.
* In September 2025, Incyte presented new 24-week interim data evaluating the safety and efficacy of povorcitinib from the pivotal Phase III STOP-HS clinical trial program in adult patients ( greater than or equal to 18 years) with moderate to severe hidradenitis suppurativa at the European Association of Dermatology and Venereology (EADV) 2025 Congress.
* In March 2025, Incyte announced positive topline results from its pivotal Phase III STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib.

What is Hidradenitis Suppurativa?

Hidradenitis suppurativa is a chronic, inflammatory skin disease characterized by recurrent, painful lumps that develop in areas where skin rubs together, such as the armpits, groin, buttocks, and under the breasts. These lesions arise due to blockage and inflammation of hair follicles, leading to abscesses, draining sinus tracts, and scarring over time. Hidradenitis suppurativa is not an infection or contagious, but it is driven by immune dysregulation and inflammation. The condition typically begins after puberty, follows a relapsing-remitting course, and can significantly impact a patient's quality of life due to pain, discharge, odor, and associated psychological distress.

Hidradenitis Suppurativa Epidemiology Segmentation

The hidradenitis suppurativa epidemiology section provides insights into the historical and current hidradenitis suppurativa patient pool and forecasted trends for the leading markets. The Gender-specific analysis suggests that hidradenitis suppurativa is more prevalent in females than males in the US and Europe, but in Japan, it is more prevalent in males than females.

The hidradenitis suppurativa treatment market reportproffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:

* Total Prevalent Cases of Hidradenitis Suppurativa
* Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa
* Gender-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa
* Age-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa
* Stage-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa
* Treated Cases of Hidradenitis Suppurativa

Hidradenitis Suppurativa Market Forecast Report Metrics

* Study Period: 2022-2036
* Coverage: 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
* Hidradenitis Suppurativa Epidemiology Segmentation: Total Prevalent Cases of Hidradenitis Suppurativa, Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa, Gender-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa, Age-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa, Stage-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa, and Treated Cases of Hidradenitis Suppurativa
* Hidradenitis Suppurativa Market Size in 2025: USD 1.7 Billion
* Key Hidradenitis Suppurativa Companies: Eli Lilly, MoonLake Immunotherapeutics, Priovant Therapeutics, Boehringer Ingelheim, UNION Therapeutics, Incyte Corporation, AbbVie, UCB, Novartis Pharmaceuticals, and others
* Key Hidradenitis Suppurativa Therapies: Eltrekibart, Lutikizumab, Sonelokimab, Brepocitinib, Spesolimab, Orismilast, Povorcitinib, HUMIRA, BIMZELX, COSENTYX, and others

Scope of the Hidradenitis Suppurativa Market Report

* Therapeutic Assessment: Hidradenitis Suppurativa current marketed and emerging therapies
* Hidradenitis Suppurativa Market Dynamics: Key Market Forecast Assumptions of Emerging Hidradenitis Suppurativa Drugs and Market Outlook
* Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Unmet Needs, KOL's views, Analyst's views, Hidradenitis Suppurativa Market Access and Reimbursement

Download the report to understand factors driving HS market growth @ [https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=scpr]

Table of Contents

1. Hidradenitis Suppurativa Market Key Insights

2. Hidradenitis Suppurativa Market Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. Hidradenitis Suppurativa Market Overview at a Glance

6.1. Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [RoA])

6.3. Market Share (%) Distribution of Hidradenitis Suppurativa by Therapies in 2025 in the 7MM

6.4. Market Share (%) Distribution of Hidradenitis Suppurativa by Therapies in 2036 in the 7MM

7. Disease Overview: Hidradenitis Suppurativa

7.1. Introduction

7.2. Causes and Symptoms of Hidradenitis Suppurativa

7.3. Classification and Severity Assessment of Hidradenitis Suppurativa

7.4. Pathophysiology of Hidradenitis Suppurativa

7.5. Genetic Basis of Hidradenitis Suppurativa

7.6. Diagnosis of Hidradenitis Suppurativa

7.7. Biomarkers of Hidradenitis Suppurativa

7.8. Risk Factors and Complications

7.9. Comorbidities

8. Treatment and Guidelines

9. Epidemiology and Patient Population

9.1. Assumptions and Rationale: 7MM

9.2. Key Findings

9.3. Total Prevalent Cases of Hidradenitis Suppurativa in the 7MM

9.4. Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the 7MM

9.5. The United States

9.5.1. Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the United States

9.5.2. Gender-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the United States

9.5.3. Age-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the United States

9.5.4. Stage-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the United States

9.5.5. Treated Cases of Hidradenitis Suppurativa in the United States

9.6. EU4 and the UK

9.7. Japan

10. Hidradenitis Suppurativa Patient Journey

11. Marketed Hidradenitis Suppurativa Therapies

11.1. Key Cross Competition

11.2. Bimekizumab (BIMZELX): UCB

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Summary of Pivotal Clinical Trials

11.2.5. Analyst Views

11.3. Secukinumab (COSENTYX): Novartis Pharmaceuticals

12. Emerging Hidradenitis Suppurativa Therapies

12.1. Key Cross Competition

12.2. Povorcitinib (INCB054707): Incyte Corporation

12.2.1. Product Description

12.2.2. Clinical Development

12.2.2.1. Clinical Trials Information

12.2.3. Safety and Efficacy

12.2.4. Analyst Views

12.3. Ruxolitinib 1.5% Cream: Incyte Corporation

12.4. RINVOQ (Upadacitinib): AbbVie

12.5. Izokibep: Acelyrin

12.6. Sonelokimab (M1095): Moonlake Immunotherapeutics

12.7. Eltrekibart (LY3041658): Eli Lilly

13. Hidradenitis Suppurativa Market: 7MM Analysis

13.1. Key Findings

13.2. Hidradenitis Suppurativa Market Outlook

13.3. Conjoint Analysis

13.4. Key Hidradenitis Suppurativa Market Forecast Assumptions

13.5. Total Market Size of Hidradenitis Suppurativa in the 7MM

13.6. The United States Hidradenitis Suppurativa Market Size

13.6.1. Total Market Size of Hidradenitis Suppurativa in the United States

13.6.2. Market Size of Hidradenitis Suppurativa by Therapies in the United States

13.7. EU4 And the UK Hidradenitis Suppurativa Market Size

13.8. Japan Hidradenitis Suppurativa Market Size

14. Hidradenitis Suppurativa Market Unmet Needs

15. Hidradenitis Suppurativa Market SWOT Analysis

16. KOL Views on Hidradenitis Suppurativa

17. Hidradenitis Suppurativa Market Access And Reimbursement

17.1. The US

17.2. EU4 and the UK

17.3. Japan

17.4. Summary and Comparison of Market Access and Pricing Policy Developments in 2025

17.5. Market Access and Reimbursement of Hidradenitis Suppurativa

18. Bibliography

19. Hidradenitis Suppurativa Market Report Methodology

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hidradenitis-suppurativa-market-is-predicted-to-cross-usd-7-billion-by-2036-owing-to-the-robust-pipeline-development-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.